Metabolic reprogramming signature predicts immunotherapy efficacy in lung adenocarcinoma: Targeting <i>SLC25A1</i> to overcome immune resistance.

ABSTRACT:

Objective

Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer. Despite significant advances in immunotherapy, treatment responses vary substantially among individuals. Metabolic reprogramming, as a hallmark of cancer, plays a crucial role in tumor progression and immune evasion. However, the interplay between metabolic features and tumor immune microenvironment in LUAD remains to be systematically elucidated.

Methods

We analyzed data from 1,231 LUAD patients across seven global cohorts and developed an integrated Metabolism-Related Signature (iMRS) using machine learning approaches based on 114 metabolic features. The signature's ability to predict immunotherapy response was validated using 9 immunotherapy cohorts (n=712, including LUAD, melanoma, and glioma

SUBMITTER: Zhang P 

PROVIDER: S-EPMC12796613 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature